So we are incredibly confident about tirzepatide, not only in type two diabetes, but also we're excited to see its potential in NASH and obesity
Preclinical research demonstrates that small molecules or stabilized peptide fragments may be absorbed through these tissues, though variability in saliva, pH, and mucosal permeability affects systemic exposure
Expectations include reduced hunger, early satiety, fewer cravings, increased energy, and improvements in health metrics like cholesterol and blood pressure
Neither scenario justifies a 5-day scheduleweight loss plateaus are normal and typically resolve with time, and missing one dose by 24 hours does not require dosing adjustments
Structural and functional imaging of Muscle, Heart, Endocrine Pancreas and Kidneys in Cardiometabolic Drug Development